{"entity":{"id":"nct07051486","kind":"trial","name":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","aka":[],"tldr":"A phase 2 trial of Trastuzumab rezetecan in cervical cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT07051486 by Jiangsu HengRui Medicine Co., Ltd., with 60 participants planned, started 2025-10-11 and due to reach its primary completion in 2026-02. Interventions recorded: SHR-A1811 Injection. Conditions listed: Recurrent or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07051486","url":"https://clinicaltrials.gov/study/NCT07051486"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical","recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["trastuzumab-rezetecan"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07051486","phase":"2","setting":"A Single-Arm, Multicenter Phase II Clinical Trial of SHR-A1811 for Injection in Patients With HER2-Expressing Recurrent or Metastatic Cervical Cancer Progressing After Standard Treatment","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","started":"2025-10-11","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07051486/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}